Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici, Salih; Sahin, GÖKHAN; Ön, Sercan; Oruc, Ahmet; Eryılmaz, Melek; SAKİN, Abdullah; Coskun, Alper; Seyyar, Mustafa; Uzundere, Fatma; KÖLEMEN, ERDEM; Cabuk, Devrim; Efil, Safa; Demir, Teyfik; Turkmen, Emine; Ekinci, Ferhat; Terzi, Aytac; Sahin, Taha; Guven, Deniz; Aksoy, Sercan; Aytac, Ali; Demirkıran, Özge; Demir, Bilgin; Culcuoglu, Ismet; Ersoy, Mustafa; Asarkaya, Esra; Camanlı, Ufuk; Gezici, Barıs; Ozveren, Ahmet; Sevınc, Alper; Kitaplı, Sait; Unlu, Ahmet; Ozturk, Banu; Turkel, Alper; Dogan, Mutlu; Aslan, Ferit; Yesilbas, Enes; Kaplan, Esmanur; Sakalar, Teoman; Sahin, Elif; Emin, Gamze; Asık, ESRA; Yıldırım, Atilla; Guclu, Taliha; ugurlu, Irem; Kahvecioglu, Fatma; Hacıbekiroglu, Ilhan; Tunbekici, Ibrahim; Bayram, Selami; Kaya, Ali; Majidova, Nargiz; Yalıcı, Ozge; Karateke, Murat; Avcı, Nilufer; Belen, Burcu; Bal, Hamit; Kınıkoglu, Oguzcan; Turkoz, Fatma; Sımsek, Eda; Altınok, Oguz; Gunes, Tugce; Altıntas, Yunus; Guliyev, Murad; Ozturk, Gokhan; Erdem, Dilek; Duzkopru, Yakup; Inal, Ali; Guren, Ali; Yıldırım, Nilgun; Telli, Tugba; Danacı, Yurdagul; Aydın, Umut; Almuradova, Elvina; Yıldırım, Hasan; Gursoy, Pınar; Sendur, Mehmet; Goker, Erdem

doi:10.1002/ijc.70213

Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., ...Daha Fazla

International Journal of Cancer, 2025 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Basım Tarihi: 2025
Doi Numarası: 10.1002/ijc.70213
Dergi Adı: International Journal of Cancer
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE
Anahtar Kelimeler: real-world study, sacituzumab govitecan, triple-negative breast cancer
Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

Sacituzumab govitecan (SG) is an antibody–drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6–6.2) and 12.2 months (95% CI, 10.5–13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3–4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.